GlassScriptPhysician profile
Adrian J Baudy
NPI 1154555654
$1,470.54
in general payments reported to CMS, 2019-2025
18 companies · $678 in 2025
The $678 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $17.95 · 2021: $20.31 · 2023: $408 · 2024: $236 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.71 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $377.42 | 2025 | Tryvio |
| Mallinckrodt Hospital Products INC. | $315.13 | 2023-2025 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $167.10 | 2023 | Lupkynis |
| Vifor Pharma, INC. | $136.09 | 2019-2023 | Veltassa |
| Amgen INC. | $135.31 | 2023-2024 | Tavneos, Repatha, Otezla |
| Genzyme Corporation | $66.97 | 2019-2025 | |
| Travere Therapeutics, INC. | $40.14 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $33.07 | 2019-2024 | Jynarque |
| Pharmaessentia USA Corporation | $31.31 | 2025 | Besremi |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Calliditas Therapeutics US INC. | $23.46 | 2023 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.36 | 2025 | |
| Strongbridge US INC. | $18.98 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.95 | 2020 | |
| Shire North American Group INC | $16.81 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.55 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $15.39 | 2023 | Farxiga |
| Novo Nordisk INC | $14.89 | 2023 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Baudy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.